The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

BJU International

Volumn 104, Issue 9, 2009, Pages 1188-1190

  Chapple, Christopher ^a   De Ridder, Dirk ^b  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Botulinum toxin type A; Muscarinic antagonists; Overactive urinary bladder; Practice guidelines; Sacral neuromodulation; Therapeutics

Indexed keywords

BOTULINUM TOXIN A; DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

ALGORITHM; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONSTIPATION; DRUG EFFICACY; HUMAN; IDIOPATHIC DISEASE; INTERSTITIAL CYSTITIS; IRRITABLE COLON; LIFESTYLE MODIFICATION; NEUROLOGIC DISEASE; NEUROMODULATION; OVERACTIVE BLADDER; PELVIC ORGAN PROLAPSE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXIN TYPE A; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LUMBOSACRAL PLEXUS; MALE; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR AGENTS; PRACTICE GUIDELINES AS TOPIC; URINARY BLADDER, OVERACTIVE;

EID: 70349974923     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08777.x     Document Type: Short Survey

References (16)

1. Abrams P, Andersson KE, Birder L et al. 4th International Consultation on Incontinence. Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence, 4th edn. Paris, France : Health Publication Ltd, 2009
2. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 1314
3. Khullar V, Damiano R, Toozs-Hobson P, Cardozo L. Prevalence of faecal incontinence among women with urinary incontinence. Br J Obstet Gynaecol 1998 105 : 1211 1213
4. Thüroff J, Abrams P, Andersson KE et al. Guidelines on Urinary Incontinence. Arnhem, The Netherlands : European Association of Urology, 2005
5. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 562
6. Basra RK, Wagg A, Chapple C et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008 102 : 774 779
7. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008 112 : 1311 1318
8. Sahai A, Khan MS, Dasgupta P, The GKT Botulinum Study Group. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007 177 : 2231 2236
9. Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008 180 : 217 222
10. Schmid DM, Roy S, Sulser T, Scheiner D. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 2008 102 (Suppl. 1 7 10
11. Sahai A, Khan MS, Le Gall N, Dasgupta P. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008 71 : 455 459
12. Nakib N, Siegel S. Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation. Nat Clin Pract Urol 2008 5 : 118 119
13. Apostolidis A, Dasgupta P, Denys P et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 2009 55 : 100 120
14. TM Therapy for sacral neuromodulation: impact on treatment success and safety. Eur Urol 2008 54 : 1287 1296
15. South MMT, Romero AA, Jamison MG, Webster GD, Amundsen CL. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation. Int Urogynecol J Pelvic Floor Dysfunct 2007 18 : 1395 1398
16. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007 178 : 2029 2034